CST BLOG: Lab Expectations

The official blog of Cell Signaling Technology (CST), where we discuss what to expect from your time at the bench, share tips, tricks, and information.

Hallmarks of Cancer: Enabling Replicative Immortality

Read More
All Posts

Cancer cells can revert to a pre-differentiated, stem-cell-like phenotype, allowing uninhibited cellular division and other metabolic adaptations that enable survival in adverse conditions.

While there are multiple signaling pathways involved in these changes, two key components enable replicative immortality, Hippo and WNT. There are multiple pathways involved in this characteristic of cancer cells. Below, we'll focus on two of these key pathways: Hippo signaling and Wnt signaling.

18-CEL-47955-Hallmarks-of-Cancer-Enabling-Replicative-ImmortalityHippo signaling is an evolutionarily conserved pathway that controls organ size by regulating cell proliferation, apoptosis, and stem cell self-renewal. In addition, dysregulation of the Hippo pathway contributes to cancer development. Important targets include:

  • YAP and TAZ are key mediators to Hippo signaling. YAP acts as a transcriptional co-activator, can be phosphorylated at multiple sites, and translocates from the nucleus to the cytoplasm
  • When the Hippo pathway is turned off, YAP is phosphorylated, translocates to the nucleus, and is associated with various transcription factors, including the TEAD and YAP/TEAD complexes, which regulate the expression of genes involved in cell proliferation and apoptosis.

The Wnt/β-Catenin pathway is another evolutionarily conserved mechanism that contributed to cancer's ability to replicate indefinitely. This pathway regulates stem cell pluripotency and cell fate decisions during development. Wnt signaling has also been shown to promote nuclear accumulation of transcriptional regulators implicated in cancer, such as TAZ. Key regulators include:

  • β-Catenin is a key downstream effector in the Wnt signaling pathway. It is implicated in two major biological processes in vertebrates: early embryonic development and tumorigenesis. It can translocate to the nucleus.
  • LEF1 and TCF bind to Wnt response elements to provide docking sites for β-catenin, which translocates to the nucleus to promote the transcription of target genes upon activation of Wnt signaling.

Learn more about the pathways and proteins involved in Enabling Replicative Immortality:

Check out The Researcher's Guide to the Hallmarks of Cancer Research Targets:

Download eBook

The Hallmarks of Cancer are seminal manuscripts by Doctors Robert Weinberg and Douglas Hanahan and were published in Cell1. The authors proposed the idea that the complexity of cancer can be broken down into smaller subsets of underlying principles. The information here pertains to one Hallmark of Cancer, known as "Enabling Replicative Immortality." Other entries in this series explore the other proposed Hallmarks.

Read the additional blog posts in the Hallmarks of Cancer series to learn more:

Select References

  1. Hanahan D, Weinberg RA (January 2000). "The Hallmarks of Cancer". Cell. 100 (1): 57–70. doi:10.1016/S0092-8674(00)81683-9
  2. Hanahan D, Weinberg RA (March 2011). "Hallmarks of Cancer: the next generation". Cell. 144 (5):646-74. doi: 10.1016/j.cell.2011.02.013.

18-CEL-47955

Chris Sumner
Chris Sumner
Chris Sumner was the Editor-in-Chief of Lab Expectations. When he's not reading/writing about curing disease, he's hiking in the woods, playing guitar, or searching for the world's best lobster roll.

Recent Posts

Cell Preparation Tips for Accurate Flow Cytometry Data

Generating accurate flow cytometry data requires more than just specific and sensitive antibodies validat...
Andrea Tu, PhD Nov 6, 2024

500 Antibodies & Counting: Accelerating Discovery with CST Antibodies Validated for Simple Western Technology

Since 2022, Cell Signaling Technology (CST) and Bio-Techne have been working together to bring best-in-cl...
Chris LaBreck, PhD Oct 23, 2024

Menin-KMT2A Inhibitors: A Promising Approach to Acute Myeloid Leukemia (AML) Treatment

Accounting for about 80% of adult acute leukemias, acute myeloid leukemia (AML) is an aggressive form of ...
Homa Rahnamoun, PhD Oct 16, 2024